Clinical trials: Microscopic Polyangiitis (MPA)
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
PR3-AAV Resilient Remission or PRRR
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
- Trial name
- NCT05376319
- Testing
- Obinutuzumab, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis.
- Trial name
- RAVELOS (NCT01586858)
- Testing
- Observational
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 67 people
- Sponsor
- Johns Hopkins University
Aortitis, Cutaneous Vasculitis
VCRC Tissue Repository
The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies.
- Conditions
- Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis
- Trial name
- NCT02967068
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Granulomatosis With Polyangitis
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
Immunosuppressive therapy of granulomatosis with polyangiitis (GPA, Wegener's) and microscopic polyangiitis (MPA) has transformed the outcome from death to a strong likelihood of disease control and temporary remission.
- Trial name
- MAINEPSAN (NCT03290456)
- Testing
- Prednisone 5mg/day extended of 12 additional months
- Where
- 45 sites in France
- Volunteers
- 146 people
- Sponsor
- Hospices Civils de Lyon
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS)
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis
- Trial name
- LoDoNaVasc (NCT03482479)
- Testing
- Naltrexone Hydrochloride
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
MPA, PAN or EGPA With FFS=0
Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
To determine whether a combination of corticosteroids and azathioprine can achieve a higher remission rate and a lower subsequent relapse rate in patients with newly-diagnosed microscopic polyangiitis, polyarteritis nodosa or…
- Conditions
- MPA, PAN or EGPA With FFS=0, At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids
- Trial name
- CHUSPAN2 (NCT00647166)
- Testing
- corticosteroid and azathioprine
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Vasculitis, Wegener's Granulomatosis
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults.
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- RAVE (NCT00104299)
- Testing
- Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 197 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
ANCA Associated Vasculitis (AAV)
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
- Trial name
- NCT06868290
- Testing
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Where
- 39 sites in United States, Brazil and 6 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Wegener's Granulomatosis
WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
Remission of ANCA-associated vasculitis can be obtained in approximately 80% of the patients with a combination of corticosteroids and cyclophosphamide. However, relapses are frequent.
- Trial name
- NCT00349674
- Testing
- Azathioprine: 2 mg/kg/day, methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Hospices Civils de Lyon
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Iptacopan in Patients With ANCA Associated Vasculitis
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or…
- Trial name
- NCT06388941
- Testing
- Iptacopan, Rituximab
- Where
- 40 sites in United States, Argentina and 13 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis
Low-dose Glucocorticoid Vasculitis Induction Study
Previous reports suggested conventional immunosuppressants such as cyclophosphamide could not reduce glucocorticoid dose in remission induction in ANCA-associated vasculitis because of lower remission rate and higher relapse…
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
- Trial name
- LoVAS (NCT02198248)
- Testing
- Rituximab, Glucocorticoids
- Where
- 17 sites in Japan
- Volunteers
- 140 people
- Sponsor
- Chiba University
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
This prospective study will assess if 12 months of vitamin D3 (cholecalciferol) supplementation, in patients with AAV (GPA, MPA, and EGPA) who have deficient or insufficient 25(OH)D3 status at enrollment, correlates with improved…
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Eosinophilic Granulomatosis With Polyangiitis
- Trial name
- PRAVDA (NCT04280601)
- Testing
- vitamin D
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Christian Pagnoux